Kathy Sue Albain, MD
Medical Oncology, Hematology & Oncology, Internal Medicine
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
888-584-7888
Services & Specialties
Areas of Specialization
- Hematology & Oncology
- Internal Medicine
- Medical Oncology
Clinical Interests
Conditions Treated
- maintenance chemotherapy
- adjuvant chemotherapy
- breast cancer biological targeted therapy
- breast cancer chemotherapy
- breast cancer genetic testing
- breast cancer therapy
- cancer chemotherapy
- breast cancer genetics
- cancer genomics
- cancer immunotherapy
- consolidation chemotherapy
- induction chemotherapy
- lung cancer genomics
- targeted molecular therapy
- Breast Cancer
- lung cancer
Locations & Contact
Primary Location
Loyola University Medical Center
2160 S First Ave
Maywood
, IL 60153
View hours
Tuesday
8:00am
- 5:00pm
Monday
8:00am
- 5:00pm
Wednesday
8:00am
- 5:00pm
Thursday
8:00am
- 5:00pm
Friday
8:00am
- 5:00pm
Saturday
8:00am
- 5:00pm
Sunday
8:00am
- 5:00pm
About
Kathy S. Albain, M.D., FACP, FASCO is Professor of Medicine (with Tenure) at the Stritch School of Medicine of Loyola University Chicago. She was named the inaugural Huizenga Family Endowed Chair in Oncology Research in 2017. She was awarded Loyola's highest honor, the Stritch Medal, in 2018.
She is a member of the Division of Hematology/Oncology and devotes her clinical practice to patients with breast and lung cancer at Loyola’s Cardinal Bernardin Cancer Center. She is Director of its Breast Clinical Research Program, Co-director of the multidisciplinary Breast Oncology Center, and Director of the Thoracic Oncology Program.
Dr. Albain's national research and advisory activities have pertained to breast and lung cancers, cancer survivorship and special populations research. She chaired the SWOG Committee on Special Populations . She was recognized for over a decade of this work in 2003 with the Susan G. Komen Professor of Survivorship award. Dr. Albain then served as co-chair of the SWOG Cancer Survivorship Committee through 2010. In 2019 Dr. Albain was appointed Vice Chair of SWOG for Clinical Trials Partnerships. The American Society of Clinical Oncology recognized Dr. Albain with its 2022 Gianni Bonadonna Breast Cancer Award and Lecture in recognition of her years of pioneering work in breast cancer research and efforts in mentoring up-and-coming researchers in the field.
Dr. Albain is a member of SWOG’s working groups for breast and lung cancer, devoting her career to research in both diseases, She is a member of the international Early Breast Cancer Trialists’ Collaborative Group and its Steering Committee. She served on the National Cancer Institute Concept Evaluation Panel for lung cancer. She was a charter member of the NIH Committee on Research on Women’s Health and served on the Oncologic Drugs Advisory Committee of the FDA. She is site Principal Investigator and New Agents Committee member for the I-SPY 2 early breast cancer research consortium.
She is a summa cum laude graduate of Wheaton College in Wheaton, Illinois, where she majored in chemistry and minored in music and biology. She graduated from the University of Michigan Medical School. Dr. Albain received postgraduate training in Internal Medicine and Hematology/Oncology at the University of Illinois and University of Chicago, respectively.
Academic Title
Professor
Leadership Title
Huizenga Family Endowed Chair in Oncology Research
Ages Seen
Adults - 18 to 64
Adults - Over 65
Procedures Performed
- cancer
Additional Resources
Education & Certifications
Education
Education:
Wheaton College
(1974)
Education:
University of Michigan Medical School
(1978)
Residency:
University of Illinois Medical Center
(1981)
Fellowship:
The University of Chicago Hospitals and Health System
(1984)
Board Certifications
Medical Oncology, Medical Oncology, American Board of Internal Medicine Subspecialty (1983)
American Board of Internal Medicine (1983)
American Board of Internal Medicine (1981)
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Publications
- Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Shatsky, R. A.; Trivedi, M. S.; Yau, C.; Nanda, R.; Rugo, H. S.; Davidian, M.; Tsiatis, B.; Wallace, A. M.; Chien, A. J.; Stringer-Reasor, E.; Boughey, J. C.; Omene, C.; Rozenblit, M.; Kalinsky, K.; Elias, A. D.; Vaklavas, C.; Beckwith, H.; Williams, N.; Arora, M.; Nangia, C.; Roussos Torres, E. T.; Thomas, B.; Albain, K. S.; Clark, A. S.; Falkson, C.; Hershman, D. L.; Isaacs, C.; Thomas, A.; Tseng, J.; Sanford, A.; Yeung, K.; Boles, S.; Chen, Y. Y.; Huppert, L.; Jahan, N.; Parker, C.; Giridhar, K.; Howard, F. M.; Blackwood, M. M.; Sanft, T.; Li, W.; Onishi, N.; Asare, A. L.; Beineke, P.; Norwood, P.; Brown-Swigart, L.; Hirst, G. L.; Matthews, J. B.; Moore, B.; Symmans, W. F.; Price, E.; Heditsian, D.; LeStage, B.; Perlmutter, J.; Pohlmann, P.; DeMichele, A.; Yee, D.; van 't Veer, L. J.; Hylton, N. M.; Esserman, L. J.; Nature medicine
- Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Khoury, K.; Meisel, J. L.; Yau, C.; Rugo, H. S.; Nanda, R.; Davidian, M.; Tsiatis, B.; Chien, A. J.; Wallace, A. M.; Arora, M.; Rozenblit, M.; Hershman, D. L.; Zimmer, A.; Clark, A. S.; Beckwith, H.; Elias, A. D.; Stringer-Reasor, E.; Boughey, J. C.; Nangia, C.; Vaklavas, C.; Omene, C.; Albain, K. S.; Kalinsky, K. M.; Isaacs, C.; Tseng, J.; Roussos Torres, E. T.; Thomas, B.; Thomas, A.; Sanford, A.; Balassanian, R.; Ewing, C.; Yeung, K.; Sauder, C.; Sanft, T.; Pusztai, L.; Trivedi, M. S.; Outhaythip, A.; Li, W.; Onishi, N.; Asare, A. L.; Beineke, P.; Norwood, P.; Brown-Swigart, L.; Hirst, G. L.; Matthews, J. B.; Moore, B.; Fraser Symmans, W.; Price, E.; Beedle, C.; Perlmutter, J.; Pohlmann, P.; Shatsky, R. A.; DeMichele, A.; Yee, D.; van 't Veer, L. J.; Hylton, N. M.; Esserman, L. J.; Nature medicine
- Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival. Sparano, J. A.; Crager, M.; Gray, R. J.; Tang, G.; Hoag, J.; Baehner, F. L.; Shak, S.; Makower, D. F.; Albain, K. S.; Hayes, D. F.; Geyer, C. E.; Dees, E. C.; Goetz, M. P.; Olson, J. A.; Lively, T.; Badve, S. S.; Saphner, T. J.; Whelan, T. J.; Kaklamani, V. G.; Wolmark, N.; Sledge, G. W.; Stemmer, S. M.; NEJM evidence
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. Tarantino, P.; Tayob, N.; Villacampa, G.; Dang, C.; Yardley, D. A.; Isakoff, S. J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Weckstein, D.; Wolff, A. C.; Reeder-Hayes, K.; Rugo, H. S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V. K.; Constantine, M.; Cheng, K.; Garrett, A. M.; Marcom, P. K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R. C.; Rimawi, M.; Abramson, V.; Pohlmann, P. R.; Van Poznak, C.; Forero-Torres, A.; Liu, M. C.; Ruddy, K. J.; Waks, A. G.; DeMeo, M.; Burstein, H. J.; Partridge, A. H.; Dell'Orto, P.; Russo, L.; Krause, E.; Newhouse, D. J.; Kurt, B. B.; Mittendorf, E. A.; Schneider, B.; Prat, A.; Winer, E. P.; Krop, I. E.; Tolaney, S. M.; Consortium of the TBCRC Translational Investigators; TBCRC Translational Investigators; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221. Chen, C. S.; Zirpoli, G.; Budd, G. T.; Barlow, W. E.; Pusztai, L.; Hortobagyi, G. N.; Albain, K. S.; Godwin, A. K.; Thompson, A.; Henry, N. L.; Ambrosone, C. B.; Stringer, K. A.; Hertz, D. L.; Cancer chemotherapy and pharmacology
- TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Bardia, A.; Pusztai, L.; Albain, K.; Ciruelos, E. M.; Im, S. A.; Hershman, D.; Kalinsky, K.; Isaacs, C.; Loirat, D.; Testa, L.; Tokunaga, E.; Wu, J.; Dry, H.; Barlow, W.; Kozarski, R.; Maxwell, M.; Harbeck, N.; Sharma, P.; Therapeutic advances in medical oncology
- Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Albain, K. S.; Yau, C.; Petricoin, E. F.; Wolf, D. M.; Lang, J. E.; Chien, A. J.; Haddad, T.; Forero-Torres, A.; Wallace, A. M.; Kaplan, H.; Pusztai, L.; Euhus, D.; Nanda, R.; Elias, A. D.; Clark, A. S.; Godellas, C.; Boughey, J. C.; Isaacs, C.; Tripathy, D.; Lu, J.; Yung, R. L.; Gallagher, R. I.; Wulfkuhle, J. D.; Brown-Swigart, L.; Krings, G.; Chen, Y. Y.; Potter, D. A.; Stringer-Reasor, E.; Blair, S.; Asare, S. M.; Wilson, A.; Hirst, G. L.; Singhrao, R.; Buxton, M.; Clennell, J. L.; Sanil, A.; Berry, S.; Asare, A. L.; Matthews, J. B.; DeMichele, A. M.; Hylton, N. M.; Melisko, M.; Perlmutter, J.; Rugo, H. S.; Symmans, W. F.; Van't Veer, L. J.; Yee, D.; Berry, D. A.; Esserman, L. J.; Clinical cancer research : an official journal of the American Association for Cancer Research
- Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. Chen, C. S.; Zirpoli, G.; Barlow, W. E.; Budd, G. T.; McKiver, B.; Pusztai, L.; Hortobagyi, G. N.; Albain, K. S.; Damaj, M. I.; Godwin, A. K.; Thompson, A.; Henry, N. L.; Ambrosone, C. B.; Stringer, K. A.; Hertz, D. L.; Journal of the National Comprehensive Cancer Network : JNCCN
- Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221. Chen, C. S.; Zirpoli, G.; Thomas Budd, G.; Barlow, W. E.; Pusztai, L.; Hortobagyi, G. N.; Albain, K. S.; Godwin, A. K.; Thompson, A.; Lynn Henry, N.; Ambrosone, C. B.; Stringer, K. A.; Hertz, D. L.; Research square
- Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. Rutherford, D. V.; Medley, S.; Henderson, N. C.; Gersch, C. L.; Vandenberg, T. A.; Albain, K. S.; Dakhil, S. R.; Tirumali, N. R.; Gralow, J. R.; Hortobagyi, G. N.; Pusztai, L.; Mehta, R. S.; Hayes, D. F.; Kidwell, K. M.; Henry, N. L.; Barlow, W. E.; Rae, J. M.; Hertz, D. L.; Pharmacogenomics
- Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Magbanua, M. J. M.; Brown Swigart, L.; Ahmed, Z.; Sayaman, R. W.; Renner, D.; Kalashnikova, E.; Hirst, G. L.; Yau, C.; Wolf, D. M.; Li, W.; Delson, A. L.; Asare, S.; Liu, M. C.; Albain, K.; Chien, A. J.; Forero-Torres, A.; Isaacs, C.; Nanda, R.; Tripathy, D.; Rodriguez, A.; Sethi, H.; Aleshin, A.; Rabinowitz, M.; Perlmutter, J.; Symmans, W. F.; Yee, D.; Hylton, N. M.; Esserman, L. J.; DeMichele, A. M.; Rugo, H. S.; van 't Veer, L. J.; Cancer cell
- Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. Cannioto, R. A.; Attwood, K. M.; Davis, E. W.; Mendicino, L. A.; Hutson, A.; Zirpoli, G. R.; Tang, L.; Nair, N. M.; Barlow, W.; Hershman, D. L.; Unger, J. M.; Moore, H. C. F.; Isaacs, C.; Hobday, T. J.; Hortobagyi, G. N.; Gralow, J. R.; Albain, K. S.; Budd, G. T.; Ambrosone, C. B.; JAMA network open
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Tolaney, S. M.; Tarantino, P.; Graham, N.; Tayob, N.; Parè, L.; Villacampa, G.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M. J.; Shapira, I.; Wolff, A. C.; Carey, L. A.; Barroso-Sousa, R.; Villagrasa, P.; DeMeo, M.; DiLullo, M.; Zanudo, J. G. T.; Weiss, J.; Wagle, N.; Partridge, A. H.; Waks, A. G.; Hudis, C. A.; Krop, I. E.; Burstein, H. J.; Prat, A.; Winer, E. P.; The Lancet. Oncology
- Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. Speers, C. W.; Symmans, W. F.; Barlow, W. E.; Trevarton, A.; The, S.; Du, L.; Rae, J. M.; Shak, S.; Baehner, R.; Sharma, P.; Pusztai, L.; Hortobagyi, G. N.; Hayes, D. F.; Albain, K. S.; Godwin, A.; Thompson, A.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Bergqvist, M.; Nordmark, A.; Williams, A.; Paoletti, C.; Barlow, W.; Cobain, E. F.; Mehta, R. S.; Gralow, J. R.; Hortobagyi, G. N.; Albain, K. S.; Pusztai, L.; Sharma, P.; Godwin, A. K.; Thompson, A. M.; Hayes, D. F.; Rae, J. M.; Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
- Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer. Khouzam, M. S.; Wood, D. E.; Vigneswaran, W.; Goyal, A.; Czerlanis, C.; Blackmon, S. H.; Donington, J.; Albain, K. S.; Freeman, R. K.; Abdelsattar, Z. M.; The Annals of thoracic surgery
- Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. Lang, J. E.; Forero-Torres, A.; Yee, D.; Yau, C.; Wolf, D.; Park, J.; Parker, B. A.; Chien, A. J.; Wallace, A. M.; Murthy, R.; Albain, K. S.; Ellis, E. D.; Beckwith, H.; Haley, B. B.; Elias, A. D.; Boughey, J. C.; Yung, R. L.; Isaacs, C.; Clark, A. S.; Han, H. S.; Nanda, R.; Khan, Q. J.; Edmiston, K. K.; Stringer-Reasor, E.; Price, E.; Joe, B.; Liu, M. C.; Brown-Swigart, L.; Petricoin, E. F.; Wulfkuhle, J. D.; Buxton, M.; Clennell, J. L.; Sanil, A.; Berry, S.; Asare, S. M.; Wilson, A.; Hirst, G. L.; Singhrao, R.; Asare, A. L.; Matthews, J. B.; Melisko, M.; Perlmutter, J.; Rugo, H. S.; Symmans, W. F.; van 't Veer, L. J.; Hylton, N. M.; DeMichele, A. M.; Berry, D. A.; Esserman, L. J.; NPJ breast cancer
- Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Marczyk, M.; Mrukwa, A.; Yau, C.; Wolf, D.; Chen, Y. Y.; Balassanian, R.; Nanda, R.; Parker, B. A.; Krings, G.; Sattar, H.; Zeck, J. C.; Albain, K. S.; Boughey, J. C.; Liu, M. C.; Elias, A. D.; Clark, A. S.; Venters, S. J.; Shad, S.; Basu, A.; Asare, S. M.; Buxton, M.; Asare, A. L.; Rugo, H. S.; Perlmutter, J.; DeMichele, A. M.; Yee, D.; Berry, D. A.; Veer, L. V.; Symmans, W. F.; Esserman, L.; Pusztai, L.; I-SPY Consortium; Annals of oncology : official journal of the European Society for Medical Oncology
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Barroso-Sousa, R.; Tarantino, P.; Tayob, N.; Dang, C.; Yardley, D. A.; Isakoff, S. J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; Weckstein, D.; Wolff, A. C.; Reeder-Hayes, K.; Rugo, H. S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V. K.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, A. M.; Marcom, K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R. C.; Rimawi, M.; Abramson, V.; Pohlmann, P. R.; Van Poznak, C.; Forero-Torres, A.; Liu, M.; Ruddy, K. J.; Zheng, Y.; Rosenberg, S. M.; Gelber, R. D.; Trippa, L.; Barry, W.; DeMeo, M.; Burstein, H.; Partridge, A.; Winer, E. P.; Krop, I.; Tolaney, S. M.; NPJ breast cancer
- Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. Unger, J. M.; Vaidya, R.; Albain, K. S.; LeBlanc, M.; Minasian, L. M.; Gotay, C. C.; Henry, N. L.; Fisch, M. J.; Lee, S. M.; Blanke, C. D.; Hershman, D. L.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. Kalinsky, K.; Barlow, W. E.; Gralow, J. R.; Meric-Bernstam, F.; Albain, K. S.; Hayes, D. F.; Lin, N. U.; Perez, E. A.; Goldstein, L. J.; Chia, S. K. L.; Dhesy-Thind, S.; Rastogi, P.; Alba, E.; Delaloge, S.; Martin, M.; Kelly, C. M.; Ruiz-Borrego, M.; Gil-Gil, M.; Arce-Salinas, C. H.; Brain, E. G. C.; Lee, E. S.; Pierga, J. Y.; Bermejo, B.; Ramos-Vazquez, M.; Jung, K. H.; Ferrero, J. M.; Schott, A. F.; Shak, S.; Sharma, P.; Lew, D. L.; Miao, J.; Tripathy, D.; Pusztai, L.; Hortobagyi, G. N.; The New England journal of medicine
- Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Clark, A. S.; Yau, C.; Wolf, D. M.; Petricoin, E. F.; van 't Veer, L. J.; Yee, D.; Moulder, S. L.; Wallace, A. M.; Chien, A. J.; Isaacs, C.; Boughey, J. C.; Albain, K. S.; Kemmer, K.; Haley, B. B.; Han, H. S.; Forero-Torres, A.; Elias, A.; Lang, J. E.; Ellis, E. D.; Yung, R.; Tripathy, D.; Nanda, R.; Wulfkuhle, J. D.; Brown-Swigart, L.; Gallagher, R. I.; Helsten, T.; Roesch, E.; Ewing, C. A.; Alvarado, M.; Crane, E. P.; Buxton, M.; Clennell, J. L.; Paoloni, M.; Asare, S. M.; Wilson, A.; Hirst, G. L.; Singhrao, R.; Steeg, K.; Asare, A.; Matthews, J. B.; Berry, S.; Sanil, A.; Melisko, M.; Perlmutter, J.; Rugo, H. S.; Schwab, R. B.; Symmans, W. F.; Hylton, N. M.; Berry, D. A.; Esserman, L. J.; DeMichele, A. M.; Nature communications
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Yee, D.; Isaacs, C.; Wolf, D. M.; Yau, C.; Haluska, P.; Giridhar, K. V.; Forero-Torres, A.; Jo Chien, A.; Wallace, A. M.; Pusztai, L.; Albain, K. S.; Ellis, E. D.; Beckwith, H.; Haley, B. B.; Elias, A. D.; Boughey, J. C.; Kemmer, K.; Yung, R. L.; Pohlmann, P. R.; Tripathy, D.; Clark, A. S.; Han, H. S.; Nanda, R.; Khan, Q. J.; Edmiston, K. K.; Petricoin, E. F.; Stringer-Reasor, E.; Falkson, C. I.; Majure, M.; Mukhtar, R. A.; Helsten, T. L.; Moulder, S. L.; Robinson, P. A.; Wulfkuhle, J. D.; Brown-Swigart, L.; Buxton, M.; Clennell, J. L.; Paoloni, M.; Sanil, A.; Berry, S.; Asare, S. M.; Wilson, A.; Hirst, G. L.; Singhrao, R.; Asare, A. L.; Matthews, J. B.; Hylton, N. M.; DeMichele, A.; Melisko, M.; Perlmutter, J.; Rugo, H. S.; Fraser Symmans, W.; Van't Veer, L. J.; Berry, D. A.; Esserman, L. J.; NPJ breast cancer
- Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. Symmans, W. F.; Yau, C.; Chen, Y. Y.; Balassanian, R.; Klein, M. E.; Pusztai, L.; Nanda, R.; Parker, B. A.; Datnow, B.; Krings, G.; Wei, S.; Feldman, M. D.; Duan, X.; Chen, B.; Sattar, H.; Khazai, L.; Zeck, J. C.; Sams, S.; Mhawech-Fauceglia, P.; Rendi, M.; Sahoo, S.; Ocal, I. T.; Fan, F.; LeBeau, L. G.; Vinh, T.; Troxell, M. L.; Chien, A. J.; Wallace, A. M.; Forero-Torres, A.; Ellis, E.; Albain, K. S.; Murthy, R. K.; Boughey, J. C.; Liu, M. C.; Haley, B. B.; Elias, A. D.; Clark, A. S.; Kemmer, K.; Isaacs, C.; Lang, J. E.; Han, H. S.; Edmiston, K.; Viscusi, R. K.; Northfelt, D. W.; Khan, Q. J.; Leyland-Jones, B.; Venters, S. J.; Shad, S.; Matthews, J. B.; Asare, S. M.; Buxton, M.; Asare, A. L.; Rugo, H. S.; Schwab, R. B.; Helsten, T.; Hylton, N. M.; van 't Veer, L.; Perlmutter, J.; DeMichele, A. M.; Yee, D.; Berry, D. A.; Esserman, L. J.; JAMA oncology
- Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Paoletti, C.; Barlow, W. E.; Cobain, E. F.; Bergqvist, M.; Mehta, R. S.; Gralow, J. R.; Hortobagyi, G. N.; Albain, K. S.; Pusztai, L.; Sharma, P.; Godwin, A. K.; Thompson, A. M.; Hayes, D. F.; Rae, J. M.; Clinical cancer research : an official journal of the American Association for Cancer Research
- Socioeconomic Disparities in Non-Small Cell Lung Cancer With Brain Metastases at Presentation: A Population-Based Study. Jusue-Torres, I.; Hulbert, A.; Zakaria, J.; Albain, K. S.; Hentz, C. L.; Melian, E.; Thakkar, J. P.; Prabhu, V. C.; World neurosurgery
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Pusztai, L.; Yau, C.; Wolf, D. M.; Han, H. S.; Du, L.; Wallace, A. M.; String-Reasor, E.; Boughey, J. C.; Chien, A. J.; Elias, A. D.; Beckwith, H.; Nanda, R.; Albain, K. S.; Clark, A. S.; Kemmer, K.; Kalinsky, K.; Isaacs, C.; Thomas, A.; Shatsky, R.; Helsten, T. L.; Forero-Torres, A.; Liu, M. C.; Brown-Swigart, L.; Petricoin, E. F.; Wulfkuhle, J. D.; Asare, S. M.; Wilson, A.; Singhrao, R.; Sit, L.; Hirst, G. L.; Berry, S.; Sanil, A.; Asare, A. L.; Matthews, J. B.; Perlmutter, J.; Melisko, M.; Rugo, H. S.; Schwab, R. B.; Symmans, W. F.; Yee, D.; Van't Veer, L. J.; Hylton, N. M.; DeMichele, A. M.; Berry, D. A.; Esserman, L. J.; Cancer cell
- Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Ruddy, K. J.; Zheng, Y.; Tayob, N.; Hu, J.; Dang, C. T.; Yardley, D. A.; Isakoff, S. J.; Valero, V. V.; Faggen, M. G.; Mulvey, T. M.; Bose, R.; Sella, T.; Weckstein, D. J.; Wolff, A. C.; Reeder-Hayes, K. E.; Rugo, H. S.; Ramaswamy, B.; Zuckerman, D. S.; Hart, L. L.; Gadi, V. K.; Constantine, M.; Cheng, K. L.; Briccetti, F. M.; Schneider, B. P.; Merrill Garrett, A.; Kelly Marcom, P.; Albain, K. S.; DeFusco, P. A.; Tung, N. M.; Ardman, B. M.; Nanda, R.; Jankowitz, R. C.; Rimawi, M.; Abramson, V.; Pohlmann, P. R.; Van Poznak, C.; Forero-Torres, A.; Liu, M. C.; Rosenberg, S.; DeMeo, M. K.; Burstein, H. J.; Winer, E. P.; Krop, I. E.; Partridge, A. H.; Tolaney, S. M.; Breast cancer research and treatment
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Tolaney, S. M.; Tayob, N.; Dang, C.; Yardley, D. A.; Isakoff, S. J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; Weckstein, D.; Wolff, A. C.; Reeder-Hayes, K.; Rugo, H. S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V. K.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, A. M.; Marcom, K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R. C.; Rimawi, M.; Abramson, V.; Pohlmann, P. R.; Van Poznak, C.; Forero-Torres, A.; Liu, M.; Ruddy, K.; Zheng, Y.; Rosenberg, S. M.; Gelber, R. D.; Trippa, L.; Barry, W.; DeMeo, M.; Burstein, H.; Partridge, A.; Winer, E. P.; Krop, I.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Argiris, A.; Miao, J.; Cristea, M. C.; Chen, A. M.; Sands, J. M.; Decker, R. H.; Gettinger, S. N.; Daly, M. E.; Faller, B. A.; Albain, K. S.; Yanagihara, R. H.; Garland, L. L.; Byers, L. A.; Wang, D.; Koczywas, M.; Redman, M. W.; Kelly, K.; Gandara, D. R.; Clinical lung cancer
- Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. Albain, K. S.; Gray, R. J.; Makower, D. F.; Faghih, A.; Hayes, D. F.; Geyer, C. E.; Dees, E. C.; Goetz, M. P.; Olson, J. A.; Lively, T.; Badve, S. S.; Saphner, T. J.; Wagner, L. I.; Whelan, T. J.; Ellis, M. J.; Wood, W. C.; Keane, M. M.; Gomez, H. L.; Reddy, P. S.; Goggins, T. F.; Mayer, I. A.; Brufsky, A. M.; Toppmeyer, D. L.; Kaklamani, V. G.; Berenberg, J. L.; Abrams, J.; Sledge, G. W.; Sparano, J. A.; Journal of the National Cancer Institute
- DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development. Peiffer, D. S.; Ma, E.; Wyatt, D.; Albain, K. S.; Osipo, C.; NPJ breast cancer
- Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. I-SPY2 Trial Consortium; Yee, D.; DeMichele, A. M.; Yau, C.; Isaacs, C.; Symmans, W. F.; Albain, K. S.; Chen, Y. Y.; Krings, G.; Wei, S.; Harada, S.; Datnow, B.; Fadare, O.; Klein, M.; Pambuccian, S.; Chen, B.; Adamson, K.; Sams, S.; Mhawech-Fauceglia, P.; Magliocco, A.; Feldman, M.; Rendi, M.; Sattar, H.; Zeck, J.; Ocal, I. T.; Tawfik, O.; LeBeau, L. G.; Sahoo, S.; Vinh, T.; Chien, A. J.; Forero-Torres, A.; Stringer-Reasor, E.; Wallace, A. M.; Pusztai, L.; Boughey, J. C.; Ellis, E. D.; Elias, A. D.; Lu, J.; Lang, J. E.; Han, H. S.; Clark, A. S.; Nanda, R.; Northfelt, D. W.; Khan, Q. J.; Viscusi, R. K.; Euhus, D. M.; Edmiston, K. K.; Chui, S. Y.; Kemmer, K.; Park, J. W.; Liu, M. C.; Olopade, O.; Leyland-Jones, B.; Tripathy, D.; Moulder, S. L.; Rugo, H. S.; Schwab, R.; Lo, S.; Helsten, T.; Beckwith, H.; Haugen, P.; Hylton, N. M.; Van't Veer, L. J.; Perlmutter, J.; Melisko, M. E.; Wilson, A.; Peterson, G.; Asare, A. L.; Buxton, M. B.; Paoloni, M.; Clennell, J. L.; Hirst, G. L.; Singhrao, R.; Steeg, K.; Matthews, J. B.; Asare, S. M.; Sanil, A.; Berry, S. M.; Esserman, L. J.; Berry, D. A.; JAMA oncology
- Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. Wagner, L. I.; Gray, R. J.; Sparano, J. A.; Whelan, T. J.; Garcia, S. F.; Yanez, B.; Tevaarwerk, A. J.; Carlos, R. C.; Albain, K. S.; Olson, J. A.; Goetz, M. P.; Pritchard, K. I.; Hayes, D. F.; Geyer, C. E.; Dees, E. C.; McCaskill-Stevens, W. J.; Minasian, L. M.; Sledge, G. W.; Cella, D.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. Cannioto, R. A.; Hutson, A.; Dighe, S.; McCann, W.; McCann, S. E.; Zirpoli, G. R.; Barlow, W.; Kelly, K. M.; DeNysschen, C. A.; Hershman, D. L.; Unger, J. M.; Moore, H. C. F.; Stewart, J. A.; Isaacs, C.; Hobday, T. J.; Salim, M.; Hortobagyi, G. N.; Gralow, J. R.; Albain, K. S.; Budd, G. T.; Ambrosone, C. B.; Journal of the National Cancer Institute
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. Nanda, R.; Liu, M. C.; Yau, C.; Shatsky, R.; Pusztai, L.; Wallace, A.; Chien, A. J.; Forero-Torres, A.; Ellis, E.; Han, H.; Clark, A.; Albain, K.; Boughey, J. C.; Jaskowiak, N. T.; Elias, A.; Isaacs, C.; Kemmer, K.; Helsten, T.; Majure, M.; Stringer-Reasor, E.; Parker, C.; Lee, M. C.; Haddad, T.; Cohen, R. N.; Asare, S.; Wilson, A.; Hirst, G. L.; Singhrao, R.; Steeg, K.; Asare, A.; Matthews, J. B.; Berry, S.; Sanil, A.; Schwab, R.; Symmans, W. F.; van 't Veer, L.; Yee, D.; DeMichele, A.; Hylton, N. M.; Melisko, M.; Perlmutter, J.; Rugo, H. S.; Berry, D. A.; Esserman, L. J.; JAMA oncology
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. Chien, A. J.; Tripathy, D.; Albain, K. S.; Symmans, W. F.; Rugo, H. S.; Melisko, M. E.; Wallace, A. M.; Schwab, R.; Helsten, T.; Forero-Torres, A.; Stringer-Reasor, E.; Ellis, E. D.; Kaplan, H. G.; Nanda, R.; Jaskowiak, N.; Murthy, R.; Godellas, C.; Boughey, J. C.; Elias, A. D.; Haley, B. B.; Kemmer, K.; Isaacs, C.; Clark, A. S.; Lang, J. E.; Lu, J.; Korde, L.; Edmiston, K. K.; Northfelt, D. W.; Viscusi, R. K.; Yee, D.; Perlmutter, J.; Hylton, N. M.; Van't Veer, L. J.; DeMichele, A.; Wilson, A.; Peterson, G.; Buxton, M. B.; Paoloni, M.; Clennell, J.; Berry, S.; Matthews, J. B.; Steeg, K.; Singhrao, R.; Hirst, G. L.; Sanil, A.; Yau, C.; Asare, S. M.; Berry, D. A.; Esserman, L. J.; I-SPY 2 Consortium; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. Woodward, W. A.; Barlow, W. E.; Jagsi, R.; Buchholz, T. A.; Shak, S.; Baehner, F.; Whelan, T. J.; Davidson, N. E.; Ingle, J. N.; King, T. A.; Ravdin, P. M.; Osborne, C. K.; Tripathy, D.; Livingston, R. B.; Gralow, J. R.; Hortobagyi, G. N.; Hayes, D. F.; Albain, K. S.; JAMA oncology
- Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). Ambrosone, C. B.; Zirpoli, G. R.; Hutson, A. D.; McCann, W. E.; McCann, S. E.; Barlow, W. E.; Kelly, K. M.; Cannioto, R.; Sucheston-Campbell, L. E.; Hershman, D. L.; Unger, J. M.; Moore, H. C. F.; Stewart, J. A.; Isaacs, C.; Hobday, T. J.; Salim, M.; Hortobagyi, G. N.; Gralow, J. R.; Budd, G. T.; Albain, K. S.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. Fehrenbacher, L.; Cecchini, R. S.; Geyer, C. E.; Rastogi, P.; Costantino, J. P.; Atkins, J. N.; Crown, J. P.; Polikoff, J.; Boileau, J. F.; Provencher, L.; Stokoe, C.; Moore, T. D.; Robidoux, A.; Flynn, P. J.; Borges, V. F.; Albain, K. S.; Swain, S. M.; Paik, S.; Mamounas, E. P.; Wolmark, N.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. Sparano, J. A.; Gray, R. J.; Makower, D. F.; Albain, K. S.; Saphner, T. J.; Badve, S. S.; Wagner, L. I.; Kaklamani, V. G.; Keane, M. M.; Gomez, H. L.; Reddy, P. S.; Goggins, T. F.; Mayer, I. A.; Toppmeyer, D. L.; Brufsky, A. M.; Goetz, M. P.; Berenberg, J. L.; Mahalcioiu, C.; Desbiens, C.; Hayes, D. F.; Dees, E. C.; Geyer, C. E.; Olson, J. A.; Wood, W. C.; Lively, T.; Paik, S.; Ellis, M. J.; Abrams, J.; Sledge, G. W.; JAMA oncology
- DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy. Peiffer, D. S.; Wyatt, D.; Zlobin, A.; Piracha, A.; Ng, J.; Dingwall, A. K.; Albain, K. S.; Osipo, C.; Cancer research
- SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Edelman, M. J.; Redman, M. W.; Albain, K. S.; McGary, E. C.; Rafique, N. M.; Petro, D.; Waqar, S. N.; Minichiello, K.; Miao, J.; Papadimitrakopoulou, V. A.; Kelly, K.; Gandara, D. R.; Herbst, R. S.; Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. Sparano, J. A.; Gray, R. J.; Ravdin, P. M.; Makower, D. F.; Pritchard, K. I.; Albain, K. S.; Hayes, D. F.; Geyer, C. E.; Dees, E. C.; Goetz, M. P.; Olson, J. A.; Lively, T.; Badve, S. S.; Saphner, T. J.; Wagner, L. I.; Whelan, T. J.; Ellis, M. J.; Paik, S.; Wood, W. C.; Keane, M. M.; Gomez Moreno, H. L.; Reddy, P. S.; Goggins, T. F.; Mayer, I. A.; Brufsky, A. M.; Toppmeyer, D. L.; Kaklamani, V. G.; Berenberg, J. L.; Abrams, J.; Sledge, G. W.; The New England journal of medicine
- Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Bellon, J. R.; Guo, H.; Barry, W. T.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M.; Wolff, A. C.; Carey, L. A.; Overmoyer, B. A.; Partridge, A. H.; Hudis, C. A.; Krop, I.; Burstein, H. J.; Winer, E. P.; Tolaney, S. M.; Breast cancer research and treatment
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Tolaney, S. M.; Guo, H.; Pernas, S.; Barry, W. T.; Dillon, D. A.; Ritterhouse, L.; Schneider, B. P.; Shen, F.; Fuhrman, K.; Baltay, M.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M. J.; Shapira, I.; Wolff, A. C.; Carey, L. A.; Overmoyer, B.; Partridge, A. H.; Hudis, C. A.; Krop, I. E.; Burstein, H. J.; Winer, E. P.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. Larsen, V.; Barlow, W. E.; Yang, J. J.; Zhu, Q.; Liu, S.; Kwan, M. L.; Ergas, I. J.; Roh, J. M.; Hutchins, L. F.; Kadlubar, S. A.; Albain, K. S.; Rae, J. M.; Yeh, I. T.; Ravdin, P. M.; Martino, S.; Lyss, A. P.; Osborne, C. K.; Hortobagyi, G. N.; Kushi, L. H.; Hayes, D. F.; Ambrosone, C. B.; Yao, S.; Clinical breast cancer
- Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. Mehta, R. S.; Barlow, W. E.; Albain, K. S.; Vandenberg, T. A.; Dakhil, S. R.; Tirumali, N. R.; Lew, D. L.; Hayes, D. F.; Gralow, J. R.; Linden, H. H.; Livingston, R. B.; Hortobagyi, G. N.; The New England journal of medicine
- Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Mongiovi, J. M.; Zirpoli, G. R.; Cannioto, R.; Sucheston-Campbell, L. E.; Hershman, D. L.; Unger, J. M.; Moore, H. C. F.; Stewart, J. A.; Isaacs, C.; Hobday, T. J.; Salim, M.; Hortobagyi, G. N.; Gralow, J. R.; Thomas Budd, G.; Albain, K. S.; Ambrosone, C. B.; McCann, S. E.; Breast cancer research : BCR
- Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. Moore, H. C. F.; Unger, J. M.; Phillips, K. A.; Boyle, F.; Hitre, E.; Moseley, A.; Porter, D. J.; Francis, P. A.; Goldstein, L. J.; Gomez, H. L.; Vallejos, C. S.; Partridge, A. H.; Dakhil, S. R.; Garcia, A. A.; Gralow, J. R.; Lombard, J. M.; Forbes, J. F.; Martino, S.; Barlow, W. E.; Fabian, C. J.; Minasian, L. M.; Meyskens, F. L.; Gelber, R. D.; Hortobagyi, G. N.; Albain, K. S.; Journal of the National Cancer Institute
- Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). Greenlee, H.; Lew, D. L.; Hershman, D. L.; Newman, V. A.; Hansen, L.; Hartman, S. J.; Korner, J.; Shi, Z.; Sardo Molmenti, C. L.; Sayegh, A.; Fehrenbacher, L.; Lo, S.; Klemp, J.; Rinn, K.; Robertson, J. M.; Unger, J.; Gralow, J.; Albain, K.; Krouse, R.; Fabian, C.; Obesity (Silver Spring, Md.)
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. Sparano, J. A.; Gray, R. J.; Makower, D. F.; Pritchard, K. I.; Albain, K. S.; Hayes, D. F.; Geyer, C. E.; Dees, E. C.; Goetz, M. P.; Olson, J. A.; Lively, T.; Badve, S. S.; Saphner, T. J.; Wagner, L. I.; Whelan, T. J.; Ellis, M. J.; Paik, S.; Wood, W. C.; Ravdin, P. M.; Keane, M. M.; Gomez Moreno, H. L.; Reddy, P. S.; Goggins, T. F.; Mayer, I. A.; Brufsky, A. M.; Toppmeyer, D. L.; Kaklamani, V. G.; Berenberg, J. L.; Abrams, J.; Sledge, G. W.; The New England journal of medicine
- Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Baker, A.; Wyatt, D.; Bocchetta, M.; Li, J.; Filipovic, A.; Green, A.; Peiffer, D. S.; Fuqua, S.; Miele, L.; Albain, K. S.; Osipo, C.; Oncogene
- Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. Lambertini, M.; Moore, H. C. F.; Leonard, R. C. F.; Loibl, S.; Munster, P.; Bruzzone, M.; Boni, L.; Unger, J. M.; Anderson, R. A.; Mehta, K.; Minton, S.; Poggio, F.; Albain, K. S.; Adamson, D. J. A.; Gerber, B.; Cripps, A.; Bertelli, G.; Seiler, S.; Ceppi, M.; Partridge, A. H.; Del Mastro, L.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Response to H. Nabi et al. Cheng, T. D.; Darke, A. K.; Redman, M. W.; Kelly, K.; Santella, R. M.; Albain, K. S.; Ambrosone, C. B.; Journal of the National Cancer Institute
- Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study. Zirpoli, G. R.; McCann, S. E.; Sucheston-Campbell, L. E.; Hershman, D. L.; Ciupak, G.; Davis, W.; Unger, J. M.; Moore, H. C. F.; Stewart, J. A.; Isaacs, C.; Hobday, T. J.; Salim, M.; Hortobagyi, G. N.; Gralow, J. R.; Budd, G. T.; Albain, K. S.; Ambrosone, C. B.; Journal of the National Cancer Institute
- Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). Hershman, D. L.; Unger, J. M.; Crew, K. D.; Till, C.; Greenlee, H.; Minasian, L. M.; Moinpour, C. M.; Lew, D. L.; Fehrenbacher, L.; Wade, J. L.; Wong, S. F.; Fisch, M. J.; Lynn Henry, N.; Albain, K. S.; Journal of the National Cancer Institute
- Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). Cheng, T. D.; Darke, A. K.; Redman, M. W.; Zirpoli, G. R.; Davis, W.; Payne Ondracek, R.; Bshara, W.; Omilian, A. R.; Kratzke, R.; Reid, M. E.; Molina, J. R.; Kolesar, J. M.; Chen, Y.; MacRae, R. M.; Moon, J.; Mack, P.; Gandara, D. R.; Kelly, K.; Santella, R. M.; Albain, K. S.; Ambrosone, C. B.; Journal of the National Cancer Institute
- Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Sucheston-Campbell, L. E.; Clay-Gilmour, A. I.; Barlow, W. E.; Budd, G. T.; Stram, D. O.; Haiman, C. A.; Sheng, X.; Yan, L.; Zirpoli, G.; Yao, S.; Jiang, C.; Owzar, K.; Hershman, D.; Albain, K. S.; Hayes, D. F.; Moore, H. C.; Hobday, T. J.; Stewart, J. A.; Rizvi, A.; Isaacs, C.; Salim, M.; Gralow, J. R.; Hortobagyi, G. N.; Livingston, R. B.; Kroetz, D. L.; Ambrosone, C. B.; Pharmacogenetics and genomics
- Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. Potkul, R. K.; Unger, J. M.; Livingston, R. B.; Crew, K. D.; Wilczynski, S. P.; Salomon, C. G.; Smith, B. L.; Wong, L.; Campbell, D. L.; Einspahr, D. E.; Anderson, G. L.; Hershman, D.; Goodman, G. E.; Brown, P. H.; Meyskens, F. L.; Albain, K. S.; NPJ breast cancer
- How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? Crew, K. D.; Albain, K. S.; Hershman, D. L.; Unger, J. M.; Lo, S. S.; NPJ breast cancer
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. Rugo, H. S.; Olopade, O. I.; DeMichele, A.; Yau, C.; van 't Veer, L. J.; Buxton, M. B.; Hogarth, M.; Hylton, N. M.; Paoloni, M.; Perlmutter, J.; Symmans, W. F.; Yee, D.; Chien, A. J.; Wallace, A. M.; Kaplan, H. G.; Boughey, J. C.; Haddad, T. C.; Albain, K. S.; Liu, M. C.; Isaacs, C.; Khan, Q. J.; Lang, J. E.; Viscusi, R. K.; Pusztai, L.; Moulder, S. L.; Chui, S. Y.; Kemmer, K. A.; Elias, A. D.; Edmiston, K. K.; Euhus, D. M.; Haley, B. B.; Nanda, R.; Northfelt, D. W.; Tripathy, D.; Wood, W. C.; Ewing, C.; Schwab, R.; Lyandres, J.; Davis, S. E.; Hirst, G. L.; Sanil, A.; Berry, D. A.; Esserman, L. J.; I-SPY 2 Investigators; The New England journal of medicine
- Adaptive Randomization of Neratinib in Early Breast Cancer. Park, J. W.; Liu, M. C.; Yee, D.; Yau, C.; van 't Veer, L. J.; Symmans, W. F.; Paoloni, M.; Perlmutter, J.; Hylton, N. M.; Hogarth, M.; DeMichele, A.; Buxton, M. B.; Chien, A. J.; Wallace, A. M.; Boughey, J. C.; Haddad, T. C.; Chui, S. Y.; Kemmer, K. A.; Kaplan, H. G.; Isaacs, C.; Nanda, R.; Tripathy, D.; Albain, K. S.; Edmiston, K. K.; Elias, A. D.; Northfelt, D. W.; Pusztai, L.; Moulder, S. L.; Lang, J. E.; Viscusi, R. K.; Euhus, D. M.; Haley, B. B.; Khan, Q. J.; Wood, W. C.; Melisko, M.; Schwab, R.; Helsten, T.; Lyandres, J.; Davis, S. E.; Hirst, G. L.; Sanil, A.; Esserman, L. J.; Berry, D. A.; I-SPY 2 Investigators; The New England journal of medicine
- Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. Hertz, D. L.; Barlow, W. E.; Kidwell, K. M.; Albain, K. S.; Vandenberg, T. A.; Dakhil, S. R.; Tirumali, N. R.; Livingston, R. B.; Gralow, J.; Hayes, D. F.; Hortobagyi, G. N.; Mehta, R. S.; Rae, J. M.; British journal of clinical pharmacology
- Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Ganz, P. A.; Cecchini, R. S.; Julian, T. B.; Margolese, R. G.; Costantino, J. P.; Vallow, L. A.; Albain, K. S.; Whitworth, P. W.; Cianfrocca, M. E.; Brufsky, A. M.; Gross, H. M.; Soori, G. S.; Hopkins, J. O.; Fehrenbacher, L.; Sturtz, K.; Wozniak, T. F.; Seay, T. E.; Mamounas, E. P.; Wolmark, N.; Lancet (London, England)
- Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Margolese, R. G.; Cecchini, R. S.; Julian, T. B.; Ganz, P. A.; Costantino, J. P.; Vallow, L. A.; Albain, K. S.; Whitworth, P. W.; Cianfrocca, M. E.; Brufsky, A. M.; Gross, H. M.; Soori, G. S.; Hopkins, J. O.; Fehrenbacher, L.; Sturtz, K.; Wozniak, T. F.; Seay, T. E.; Mamounas, E. P.; Wolmark, N.; Lancet (London, England)
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. Dang, C.; Guo, H.; Najita, J.; Yardley, D.; Marcom, K.; Albain, K.; Rugo, H.; Miller, K.; Ellis, M.; Shapira, I.; Wolff, A. C.; Carey, L. A.; Moy, B.; Groarke, J.; Moslehi, J.; Krop, I.; Burstein, H. J.; Hudis, C.; Winer, E. P.; Tolaney, S. M.; JAMA oncology
- Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. Unger, J. M.; Gralow, J. R.; Albain, K. S.; Ramsey, S. D.; Hershman, D. L.; JAMA oncology
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. Sparano, J. A.; Gray, R. J.; Makower, D. F.; Pritchard, K. I.; Albain, K. S.; Hayes, D. F.; Geyer, C. E.; Dees, E. C.; Perez, E. A.; Olson, J. A.; Zujewski, J.; Lively, T.; Badve, S. S.; Saphner, T. J.; Wagner, L. I.; Whelan, T. J.; Ellis, M. J.; Paik, S.; Wood, W. C.; Ravdin, P.; Keane, M. M.; Gomez Moreno, H. L.; Reddy, P. S.; Goggins, T. F.; Mayer, I. A.; Brufsky, A. M.; Toppmeyer, D. L.; Kaklamani, V. G.; Atkins, J. N.; Berenberg, J. L.; Sledge, G. W.; The New England journal of medicine
- PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance. Pandya, K.; Wyatt, D.; Gallagher, B.; Shah, D.; Baker, A.; Bloodworth, J.; Zlobin, A.; Pannuti, A.; Green, A.; Ellis, I. O.; Filipovic, A.; Sagert, J.; Rana, A.; Albain, K. S.; Miele, L.; Denning, M. F.; Osipo, C.; Clinical cancer research : an official journal of the American Association for Cancer Research
- Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. Moore, H. C.; Unger, J. M.; Phillips, K. A.; Boyle, F.; Hitre, E.; Porter, D.; Francis, P. A.; Goldstein, L. J.; Gomez, H. L.; Vallejos, C. S.; Partridge, A. H.; Dakhil, S. R.; Garcia, A. A.; Gralow, J.; Lombard, J. M.; Forbes, J. F.; Martino, S.; Barlow, W. E.; Fabian, C. J.; Minasian, L.; Meyskens, F. L.; Gelber, R. D.; Hortobagyi, G. N.; Albain, K. S.; POEMS/S0230 Investigators; The New England journal of medicine
- The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. DeMichele, A.; Yee, D.; Berry, D. A.; Albain, K. S.; Benz, C. C.; Boughey, J.; Buxton, M.; Chia, S. K.; Chien, A. J.; Chui, S. Y.; Clark, A.; Edmiston, K.; Elias, A. D.; Forero-Torres, A.; Haddad, T. C.; Haley, B.; Haluska, P.; Hylton, N. M.; Isaacs, C.; Kaplan, H.; Korde, L.; Leyland-Jones, B.; Liu, M. C.; Melisko, M.; Minton, S. E.; Moulder, S. L.; Nanda, R.; Olopade, O. I.; Paoloni, M.; Park, J. W.; Parker, B. A.; Perlmutter, J.; Petricoin, E. F.; Rugo, H.; Symmans, F.; Tripathy, D.; van't Veer, L. J.; Viscusi, R. K.; Wallace, A.; Wolf, D.; Yau, C.; Esserman, L. J.; Clinical cancer research : an official journal of the American Association for Cancer Research
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. Tolaney, S. M.; Barry, W. T.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M.; Shapira, I.; Wolff, A. C.; Carey, L. A.; Overmoyer, B. A.; Partridge, A. H.; Guo, H.; Hudis, C. A.; Krop, I. E.; Burstein, H. J.; Winer, E. P.; The New England journal of medicine
- SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. Budd, G. T.; Barlow, W. E.; Moore, H. C.; Hobday, T. J.; Stewart, J. A.; Isaacs, C.; Salim, M.; Cho, J. K.; Rinn, K. J.; Albain, K. S.; Chew, H. K.; Burton, G. V.; Moore, T. D.; Srkalovic, G.; McGregor, B. A.; Flaherty, L. E.; Livingston, R. B.; Lew, D. L.; Gralow, J. R.; Hortobagyi, G. N.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. Miller, K. D.; Diéras, V.; Harbeck, N.; Andre, F.; Mahtani, R. L.; Gianni, L.; Albain, K. S.; Crivellari, D.; Fang, L.; Michelson, G.; de Haas, S. L.; Burris, H. A.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Phillips, G. D.; Fields, C. T.; Li, G.; Dowbenko, D.; Schaefer, G.; Miller, K.; Andre, F.; Burris, H. A.; Albain, K. S.; Harbeck, N.; Dieras, V.; Crivellari, D.; Fang, L.; Guardino, E.; Olsen, S. R.; Crocker, L. M.; Sliwkowski, M. X.; Clinical cancer research : an official journal of the American Association for Cancer Research
- Positron emission tomography-avid adrenal mass and incidental renal mass in a 70-year-old woman with newly diagnosed breast cancer. Hannick, J. H.; Wang, L.; Barkan, G. A.; Perez, C.; Bova, D.; Albain, K. S.; Quek, M. L.; Urology
- Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Yao, S.; Sucheston, L. E.; Zhao, H.; Barlow, W. E.; Zirpoli, G.; Liu, S.; Moore, H. C.; Thomas Budd, G.; Hershman, D. L.; Davis, W.; Ciupak, G. L.; Stewart, J. A.; Isaacs, C.; Hobday, T. J.; Salim, M.; Hortobagyi, G. N.; Gralow, J. R.; Livingston, R. B.; Albain, K. S.; Hayes, D. F.; Ambrosone, C. B.; The pharmacogenomics journal
- Commentary on adjuvant chemotherapy for the older woman with early stage breast cancer. Albain, K. S.; Breast (Edinburgh, Scotland)
- Impact of multigene assays in early stage breast cancer. Lo, S. S.; Albain, K. S.; The oncologist
- Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Pandya, K.; Meeke, K.; Clementz, A. G.; Rogowski, A.; Roberts, J.; Miele, L.; Albain, K. S.; Osipo, C.; British journal of cancer
- Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Albain, K. S.; Carey, L.; Gradishar, W. J.; Gralow, J. R.; Lipton, A.; Rugo, H.; Tripathy, D.; Peck, S.; Abair, T.; Pegram, M.; Clinical breast cancer
- Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Grudzien, P.; Lo, S.; Albain, K. S.; Robinson, P.; Rajan, P.; Strack, P. R.; Golde, T. E.; Miele, L.; Foreman, K. E.; Anticancer research
- Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. Lo, S. S.; Mumby, P. B.; Norton, J.; Rychlik, K.; Smerage, J.; Kash, J.; Chew, H. K.; Gaynor, E. R.; Hayes, D. F.; Epstein, A.; Albain, K. S.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Albain, K. S.; Barlow, W. E.; Shak, S.; Hortobagyi, G. N.; Livingston, R. B.; Yeh, I. T.; Ravdin, P.; Bugarini, R.; Baehner, F. L.; Davidson, N. E.; Sledge, G. W.; Winer, E. P.; Hudis, C.; Ingle, J. N.; Perez, E. A.; Pritchard, K. I.; Shepherd, L.; Gralow, J. R.; Yoshizawa, C.; Allred, D. C.; Osborne, C. K.; Hayes, D. F.; Breast Cancer Intergroup of North America; The Lancet. Oncology
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Albain, K. S.; Barlow, W. E.; Ravdin, P. M.; Farrar, W. B.; Burton, G. V.; Ketchel, S. J.; Cobau, C. D.; Levine, E. G.; Ingle, J. N.; Pritchard, K. I.; Lichter, A. S.; Schneider, D. J.; Abeloff, M. D.; Henderson, I. C.; Muss, H. B.; Green, S. J.; Lew, D.; Livingston, R. B.; Martino, S.; Osborne, C. K.; Breast Cancer Intergroup of North America; Lancet (London, England)
- Lung cancer outcomes in women. Shafer, D.; Albain, K.; Seminars in oncology
- Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Albain, K. S.; Paik, S.; van't Veer, L.; Breast (Edinburgh, Scotland)
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Albain, K. S.; Swann, R. S.; Rusch, V. W.; Turrisi, A. T.; Shepherd, F. A.; Smith, C.; Chen, Y.; Livingston, R. B.; Feins, R. H.; Gandara, D. R.; Fry, W. A.; Darling, G.; Johnson, D. H.; Green, M. R.; Miller, R. C.; Ley, J.; Sause, W. T.; Cox, J. D.; Lancet (London, England)
- Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. Albain, K. S.; Unger, J. M.; Crowley, J. J.; Coltman, C. A.; Hershman, D. L.; Journal of the National Cancer Institute
- Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. Lo, S. S.; Pritchard, K. I.; Robinson, P.; Albain, K. S.; Cancer treatment and research
- Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. Camacho, P. M.; Dayal, A. S.; Diaz, J. L.; Nabhan, F. A.; Agarwal, M.; Norton, J. G.; Robinson, P. A.; Albain, K. S.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. Albain, K. S.; Nag, S. M.; Calderillo-Ruiz, G.; Jordaan, J. P.; Llombart, A. C.; Pluzanska, A.; Rolski, J.; Melemed, A. S.; Reyes-Vidal, J. M.; Sekhon, J. S.; Simms, L.; O'Shaughnessy, J.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Rizzo, P.; Miao, H.; D'Souza, G.; Osipo, C.; Song, L. L.; Yun, J.; Zhao, H.; Mascarenhas, J.; Wyatt, D.; Antico, G.; Hao, L.; Yao, K.; Rajan, P.; Hicks, C.; Siziopikou, K.; Selvaggi, S.; Bashir, A.; Bhandari, D.; Marchese, A.; Lendahl, U.; Qin, J. Z.; Tonetti, D. A.; Albain, K.; Nickoloff, B. J.; Miele, L.; Cancer research
- PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Albain, K. S.; Belani, C. P.; Bonomi, P.; O'Byrne, K. J.; Schiller, J. H.; Socinski, M.; Clinical lung cancer
- Clinical factors used to support prophylactic mastectomy for a male BRCA2 mutation carrier. Guiahi, M.; Gabram, S. G.; Albain, K. S.; Camacho, P.; Krishnamachari, B.; Rajan, P.; Surgery
- Acute lung injury associated with vinorelbine. Tanvetyanon, T.; Garrity, E. R.; Albain, K. S.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Correlation of nipple aspiration and ductal lavage cytology with histopathologic findings for patients before scheduled breast biopsy examination. West, K. E.; Wojcik, E. M.; Dougherty, T. A.; Siziopikou, K. P.; Albain, K. S.; Gabram, S. G.; American journal of surgery
- Reducing the global breast cancer burden: the importance of patterns of care research. Albain, K. S.; de la Garza Salazar, J.; Pienkowski, T.; Aapro, M.; Bergh, J.; Caleffi, M.; Coleman, R.; Eiermann, W.; Icli, F.; Pegram, M.; Piccart, M.; Snyder, R.; Toi, M.; Hortobagyi, G. N.; Clinical breast cancer
- Multimodality therapy for stage III non-small-cell lung cancer. Farray, D.; Mirkovic, N.; Albain, K. S.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. Albain, K. S.; Crowley, J. J.; Turrisi, A. T.; Gandara, D. R.; Farrar, W. B.; Clark, J. I.; Beasley, K. R.; Livingston, R. B.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinoma. Clark, J. I.; Albain, K. S.; Cancer treatment and research
- Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer. Albain, K. S.; Current oncology reports
- PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. Nieland, J. D.; Loviscek, K.; Kono, K.; Albain, K. S.; McCall, A. R.; Potkul, R. K.; Fisher, S. G.; Velders, M. P.; Petersson, M.; Kiessling, R.; Kast, W. M.; Journal of immunotherapy (Hagerstown, Md. : 1997)
- Induction chemotherapy with/without radiation followed by surgery in stage III non-small-cell lung cancer. Albain, K. S.; Oncology (Williston Park, N.Y.)
- Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. Albain, K. S.; Green, S. R.; Lichter, A. S.; Hutchins, L. F.; Wood, W. C.; Henderson, I. C.; Ingle, J. N.; O'Sullivan, J.; Osborne, C. K.; Martino, S.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. Albain, K. S.; Rusch, V. W.; Crowley, J. J.; Rice, T. W.; Turrisi, A. T.; Weick, J. K.; Lonchyna, V. A.; Presant, C. A.; McKenna, R. J.; Gandara, D. R.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904. Albain, K. S.; Liu, P. Y.; Hantel, A.; Poplin, E. A.; O'Toole, R. V.; Wade, J. L.; Maddox, A. M.; Alberts, D. S.; Gynecologic oncology
- Breast cancer outcome and predictors of outcome: are there age differentials? Albain, K. S.; Allred, D. C.; Clark, G. M.; Journal of the National Cancer Institute. Monographs
- Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Albain, K. S.; Crowley, J. J.; Hutchins, L.; Gandara, D.; O'Bryan, R. M.; Von Hoff, D. D.; Griffin, B.; Livingston, R. B.; Cancer
- Induction therapy followed by definitive local control for stage III non-small-cell lung cancer. A review, with a focus on recent trimodality trials. Albain, K. S.; Chest
- Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience. Albain, K. S.; Swinnen, L. J.; Erickson, L. C.; Stiff, P. J.; Fisher, S. G.; Fisher, R. I.; Seminars in oncology
- Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Albain, K. S.; Green, S.; LeBlanc, M.; Rivkin, S.; O'Sullivan, J.; Osborne, C. K.; Breast cancer research and treatment
- Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. Albain, K. S.; Crowley, J. J.; LeBlanc, M.; Livingston, R. B.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Albain, K. S.; Crowley, J. J.; Livingston, R. B.; Chest
- Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. Albain, K. S.; Crowley, J. J.; LeBlanc, M.; Livingston, R. B.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation. Albain, K. S.; Le Beau, M. M.; Ullirsch, R.; Schumacher, H.; Genes, chromosomes & cancer
- Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model. Albain, K. S.; Swinnen, L. J.; Erickson, L. C.; Stiff, P. J.; Fisher, R. I.; Cancer chemotherapy and pharmacology
- Adjuvant chemotherapy and endocrine therapy for node-positive and node-negative breast carcinoma. Albain, K. S.; Clinical obstetrics and gynecology
- 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Swinnen, L. J.; Barnes, D. M.; Fisher, S. G.; Albain, K. S.; Fisher, R. I.; Erickson, L. C.; Cancer research